Related Experiment Video
Updated: Jul 7, 2026

Merging Absolute and Relative Quantitative PCR Data to Quantify STAT3 Splice Variant Transcripts
Published on: October 9, 2016
Role of IG20 splice variants in TRAIL resistance
Bellur S Prabhakar1, Nirupama Mulherkar, Kanteti V Prasad
1Department of Microbiology and Immunology, University of Illinois at Chicago, Chicago, IL 60612, USA. bprabhak@uic.edu
Abstract:
Tumor necrosis factor receptor-related apoptosis-inducing ligand (TRAIL) can induce apoptosis primarily in cancer cells with little or no effect on normal cells; therefore, it has the potential for use in cancer therapy. TRAIL binding to death receptors DR4 and DR5 triggers the death-inducing signal complex formation and activation of procaspase-8, which in turn activates caspase-3, leading to cell death. Like FasL, TRAIL can trigger type 1 (caspase-8 --> caspase-3) or type 2 (caspase-8 --> Bid cleavage --> capsase-9 --> caspase-3) apoptotic pathways depending on the cell type. Some cancers are resistant to TRAIL treatment because most molecules in the TRAIL signaling pathway, including FLIPs and IAPs, can contribute to resistance. In addition, we have identified an essential role for splice variants of the IG20 gene in TRAIL resistance.
Insights
Tumor necrosis factor receptor-related apoptosis-inducing ligand (TRAIL) shows promise for cancer therapy by inducing cancer cell death. However, cancer cells can develop resistance to TRAIL through various molecular mechanisms, including IG20 gene splice variants.
Area of Science:
- Molecular Biology
- Cell Biology
- Cancer Research
Background:
- Tumor necrosis factor receptor-related apoptosis-inducing ligand (TRAIL) selectively induces apoptosis in cancer cells, presenting a therapeutic potential.
- TRAIL initiates apoptosis by binding to death receptors (DR4/DR5), leading to caspase activation and programmed cell death.
- TRAIL-mediated apoptosis can follow Type 1 or Type 2 pathways, contingent on cellular context.
Purpose of the Study:
- To investigate the mechanisms underlying cancer cell resistance to TRAIL-induced apoptosis.
- To identify novel factors contributing to TRAIL resistance in cancer.
Main Methods:
- Analysis of TRAIL signaling pathway components.
- Investigation of the role of IG20 gene splice variants in TRAIL resistance.
Main Results:
- Cancer cells exhibit resistance to TRAIL due to factors like FLIPs and IAPs within the TRAIL pathway.
- Splice variants of the IG20 gene were identified as crucial contributors to TRAIL resistance.
Conclusions:
- Understanding TRAIL resistance mechanisms is critical for optimizing TRAIL-based cancer therapies.
- Targeting IG20 gene splice variants may represent a novel strategy to overcome TRAIL resistance in cancer treatment.
Related Concept Videos
RNA Splicing
RNA Splicing
Alternative RNA Splicing
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
Alternative RNA Splicing
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
Gene Regulation During Sporulation
Cis-regulatory Sequences
